Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Promising Results for VAC-3S

By Drug Discovery Trends Editor | July 1, 2011

InnaVirVax, biopharmaceutical company dedicated to the development of therapeutic and diagnostic solutions in pathologies associated with immune dysregulation, announces promising preclinical results of its therapeutic vaccine VAC-3S, which aims at preserving the immune system of patients infected with HIV-1.
 
Based on the understanding of the mechanism responsible for the decline of the CD4+ T lymphocytes cells during infection, the vaccine candidate VAC-3S is designed to combat the pathogenicity of the virus by blocking the decrease of the of CD4 + T lymphocytes cell count.

This vaccine approach stems from the original scientific work completed at the Pitié Salpêtrière Hospital by Prof. Patrice Debré and Dr. Vincent Vieillard (UMR INSERM and University Pierre et Marie Curie UMRS 946). This work has been released in seven international peer-reviewed journals. The VAC-3S project was supported by the French National Research Agency as part of a collaborative project with the UMRS 946 and the ‘Comissariat à l’Energie Atomique’. This support has enabled the consolidation of the proof of concept of the vaccine approach developed by InnaVirVax, specifically the protection of CD4 + T lymphocytes cells during the disease. In addition, InnaVirVax has developed a manufacturing process of the vaccine candidate, compatible with subsequent industrial use.

Studies of toxicity and local tolerance of the vaccine candidate VAC-3S have just been completed. Conducted under Good Laboratory Practice (GLP) at the CIT (Evreux, France), the results showed the absence of toxicity of the vaccine.
Launch of Phase 1/2a clinical trials. Based on the obtained results, InnaVirVax will file to the AFSSAPS, the French drug agency, a request for a Phase 1/2a clinical trial authorization.

The main objective of this trial, which will be carried out in France will focus on the safety and immunogenicity of VAC-3S in patients infected with HIV-1. Some efficacy parameters such as CD4 count, viral load and cellular activation will be studied during as secondary objective.

Joël Crouzet, CEO of InnaVirVax said, “The excellent results obtained by our vaccine candidate VAC-3S confirm the validity of our cutting edge technology protecting the immune system. Complementary to antiretrovirals that target the replication and the spread of the virus, the new class of drugs represented by VAC-3S is designed to block the pathological consequences of infection and thus the collapse of the immune system. The protection and preservation of CD4+ T lymphocyte cells represent a major challenge which could provide a tremendous response to HIV-infected patients treated or untreated with antiretroviral drugs at different stages of disease progression.”

Studies of toxicity and local tolerance of the vaccine candidate VAC-3S were performed in rats following the recommendations of regulatory agencies. Vaccine doses identical to the ones planned to be used in patients were injected intramuscularly to the animals.

Repeated VAC-3S vaccinations did not produce toxic effects and lesions both at the systemic level and at the injection site.

Date: June 30, 2011
Source: InnaVirVax 


Filed Under: Drug Discovery

 

Related Articles Read More >

FDA approved ENFLONSIA for the prevention of RSV in Infants
First clinical study results of Dupixent for atopic dermatitis in patients with darker skin tones 
Labcorp widens precision oncology toolkit, aims to speed drug-trial enrollment
Lokavant’s Spectrum v15 uses AI to cut trial-feasibility modeling from weeks to minutes
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE